Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer as an adjuvant treatment in acute aluminum phosphide poisoning
PACTR202408492665945Phase 3Not yet recruiting
- Sponsor
- Tanta University Hospitals
- Start
- Jun 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of sevelamer carbonate in Aluminium phosphide poisoning (3 arms), sponsored by Tanta University Hospitals. Primary endpoint: Mortality rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sevelamer carbonate
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on PACTR202408492665945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408492665945.